0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Carvacrol enhances anti-tumor activity and mitigates cardiotoxicity of sorafenib in thioacetamide-induced hepatocellular carcinoma model through inhibiting TRPM7.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sorafenib (Sora) represents one of the few effective drugs for the treatment of advanced hepatocellular carcinoma (HCC), while resistance and cardiotoxicity limit its therapeutic efficacy. This study investigated the effect of transient receptor potential melastatin 7 (TRPM7) inhibitor, carvacrol (CARV), on overcoming Sora resistance and cardiotoxicity in thioacetamide (TAA) induced HCC in rats.

          Related collections

          Author and article information

          Journal
          Life Sci
          Life sciences
          Elsevier BV
          1879-0631
          0024-3205
          Jul 01 2023
          : 324
          Affiliations
          [1 ] Biochemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt; Biochemistry Department, Faculty of Pharmacy, Horus University-Egypt, Damietta 34511, Egypt. Electronic address: eman.hamdi@std.mans.edu.eg.
          [2 ] Biochemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
          Article
          S0024-3205(23)00369-7
          10.1016/j.lfs.2023.121735
          37142088
          f2d661aa-e68a-4562-8014-8a7238ddbc0d
          History

          Drug resistance,Tumor microenvironment,Oxidative stress,Hypoxia-inducible factor 1 alpha,Epithelial mesenchymal transition,Cancer stemness

          Comments

          Comment on this article